Evaluating the Safety, Pharmacodynamics and Pharmacokinetics of HSK3486 in Healthy Female Subjects.

Anesthesia Clinical Trial

Official title:

A Phase 1b, Positive-controlled, Dose-escalation Study to Determine the Safety, Pharmacodynamics and Pharmacokinetics of a Single Intravenous Dose of HSK3486 in Healthy Female Subjects.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04037657
• Other study ID #: HSK3486-Australian-02
• Status: Completed
• Phase: Phase 1
• Start date: April 22, 2015
• Est. completion date: November 13, 2015

Study information

• Verified date: December 2015
• Source: Sichuan Haisco Pharmaceutical Group Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study was a single-center positive-controlled, randomized, dose-escalation study of HSK3486 in healthy female subjects administered as a single IV bolus dose.Subjects were confined to the study unit from the evening of Day -1 until the morning of Day 2, then were required to return for a follow up visit on Day 5. Intensive safety, PD and PK assessments were performed prior to dosing on Day 1 until 24 hours post-dose (Day 2).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: November 13, 2015
• Est. primary completion date: June 9, 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

• Female, aged 18 - 49 years (inclusive)

• Women of child-bearing potential agreed to use adequate contraception prior to study entry, for the duration of study participation, and for 90 days following completion of therapy

• Negative serum pregnancy test

• In general good health without CS medical history

• American Society of Anesthesiologists (ASA) Physical Status Classification of I or II

• Body Mass Index (BMI) between 18 and 30 kg/m2 (inclusive)

• Negative screen for drugs of abuse, alcohol, hepatitis B surface antigen (HBs-Ag), hepatitis C virus antibody (HCV-Ab) and Human Immunodeficiency Virus (HIV) at screening; and drugs of abuse, alcohol pre dose on Day -1

• Normal or non-CS findings on a physical examination, 12-lead Electrocardiogram (ECG) and vital signs (respiratory rate between 12 and 20 breaths per minute, blood pressure (BP) between 100-140/60-90 mmHg, heart rate between 50-99 beats per minute, temperature between 35.8°C and 37.5°C and pulse oximetry values > 95% on room air)

• Clinical laboratory values within the normal limits as defined by the clinical laboratory, unless the PI decided that out-of-range values were not CS

• Able to provide written informed consent

• Willing and able to follow study instructions and likely to complete all study requirements

• Suitable venous and arterial access

Exclusion Criteria:

• History of allergy or sensitivity to: propofol, components of Fresofol 1% MCT/LCT propofol, or HSK3486 (excipients soy bean oil, glycerine, triglycerides, purified egg phospholipids, sodium oleate and sodium hydroxide), or plain lignocaine

• History of CS problems with general anesthesia

• Current smoker, or a history of regular (more than weekly) use of tobacco- or nicotine-containing products within 2 months prior to screening

• History of excessive alcohol intake (more than four standard drinks daily, on average) or use of recreational drugs within the last 3 months CONFIDENTIAL HSK3486 SAD_02 Sichuan Haisco Pharmaceutical Co., Ltd Version: 13 Nov 2015 Page 19 of 513

• Use of prescription or over the counter medications within 7 days of Investigational Product administration, with the exception of contraceptive medications, paracetamol, oral non-steroidal anti-inflammatory agents, topical over the counter preparations and routine vitamins (if they do not exceed an intake of 20 to 600 times the recommended daily dose), unless agreed as non-clinically relevant by the PI and Sponsor.

• Standard donation of blood within 30 days of the study

• Donation of plasma or participation in a plasmapheresis program within 7 days preceding this study

• Receipt of any investigational study drug within 30 days prior to screening

• Unable to fast for the 6 hours prior to Investigational Product administration

• CS (as judged by the Investigator) presence of acute illness (e.g. gastrointestinal illness, infection such as influenza, upper respiratory tract infection) at admission to the clinical study unit

• Anticipated need for surgery or hospitalization during the study

• Anatomical abnormality that would potentially interfere with airway management under unconscious sedation or anesthesia

• History of posture-related gastric reflux more than twice weekly

• History of seizures or epilepsy

• History of ischaemic heart disease

• History of brady- or tachy-dysrhythmias requiring medical care

• History of asthma, with bronchospasm requiring treatment in the last 3 months

• Any condition, which in the Investigator's opinion, puts the subject at significant risk, could confound the study results or may interfere significantly with the subject's participation in the study.

Related Conditions & MeSH terms

• Anesthesia
• Sedation

Intervention

Drug:
• HSK3486
HSK3486 was administered as a single dose over a 1 minute infusion period. There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).
• Propofol
Propofol, at a dose of 2.5 mg/kg, was administered as a 1 minute infusion at a constant rate via infusion pump.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sichuan Haisco Pharmaceutical Group Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety by measurement of Adverse Events		First dose of study drug on day 1
Primary	Bispectral index (BIS)		From first dose of study drug until fully alert on day 1
Primary	Modified observer's assessment of alertness/sedation(MOAA/S)	Observe the change of modified observer's assessment of alert /sedation during the whole trial	Time Frame: From first dose of study drug until fully alert on day 1
Secondary	Median effective dose (ED50)		From first dose of study drug until fully alert on day 1
Secondary	Peak concentration (Cmax)		From the start of administration to 48 hours after administration
Secondary	Time to plasma peak concentration(Tmax)		From the start of administration to 48 hours after administration
Secondary	Area Under the Curve (AUC0-30min, AUC0-1h, AUC0-last, and AUC0-inf)		From the start of administration to 48 hours after administration
Secondary	Total clearance (CL)		From the start of administration to 48 hours after administration